MISOBOLD - Prostate cancer hypoxia using BOLD MRI and 18F-FMISO PET imaging - MISOBOLD

CHU de Bordeaux0 个研究点目标入组 20 人开始时间: 2017年7月12日最近更新: 2018年1月8日

适应症

试验速览

暂无简介。

•Patient above 18 yrs old.
•Prostate tumor with histological confirmed diagnosis and highly radiological suspected target on MRI
•High risk patient : >T2c grade, Glasgow score > 7 and PSA > 20ng/ml
•Surgical treatment chosen during multidisciplinary meeting
•Patient must have undergone MRI with BOLD sequence less than 6 month prior surgery
•Informed signed consent.
•Member or beneficiary of a social security system.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•Patient included in another clinical study
•Geographical, social or psychological reasons preventing patient from submitting to the study’s medical monitoring
•Patient deprive of liberty, adult subjects to legal protection or unable to give consent
•Contraindication to MRI
•Contraindication to gadolinium injection

发起方

CHU de Bordeaux